Holen Sie sich die Stockscreener-App
2.99
2.93%
-0.08
Schlusskurs vom Vortag:
$3.07
Offen:
$2.91
24-Stunden-Volumen:
26,256
Relative Volume:
0.63
Marktkapitalisierung:
$47.47M
Einnahmen:
$22.06M
Nettoeinkommen (Verlust:
$-30.94M
KGV:
-1.0034
EPS:
-2.98
Netto-Cashflow:
$-26.70M
1W Leistung:
+12.45%
1M Leistung:
-24.94%
6M Leistung:
-39.18%
1J Leistung:
-53.07%
1-Tages-Spanne:
$2.8901
$3.1566
1-Wochen-Bereich:
$2.50
$3.47
52-Wochen-Spanne:
$2.05
$8.19
Casi Pharmaceuticals Inc Stock (CASI) Company Profile
Firmenname
Casi Pharmaceuticals Inc
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie CASI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CASI
Casi Pharmaceuticals Inc
|
2.99 | 47.47M | 22.06M | -30.94M | -26.70M | -2.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
406.33 | 105.75B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
712.87 | 78.76B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
629.39 | 37.79B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
238.52 | 31.28B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
114.63 | 27.28B | 3.30B | -501.07M | 1.03B | -2.1146 |
Casi Pharmaceuticals Inc Stock (CASI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-05-18 | Eingeleitet | BTIG Research | Buy |
| 2021-04-26 | Eingeleitet | Mizuho | Buy |
| 2020-10-23 | Eingeleitet | Oppenheimer | Outperform |
| 2016-09-22 | Eingeleitet | Maxim Group | Buy |
| 2015-10-29 | Fortgesetzt | H.C. Wainwright | Buy |
| 2015-06-23 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Casi Pharmaceuticals Inc Aktie (CASI) Neueste Nachrichten
CASI Pharmaceuticals, Inc. Announces Clinical Hold of CID-103 for Antibody Mediated Rejection of Kidney Transplant - Marketscreener.com
CASI Pharmaceuticals Faces Clinical Hold on CID-103 by FDA - TipRanks
CASI PHARMACEUTICALS TO PARTICIPATE IN THE 2024 H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCE - The Eastern Progress Online
CASI Pharmaceuticals Faces Evomela® License Termination Dispute - TipRanks
The Market Doesn't Like What It Sees From CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Revenues Yet As Shares Tumble 34% - Simply Wall St
CASI Pharmaceuticals Insider Ups Holding By 65% During Year - Simply Wall St
CASI Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Earnings Flash (CASI) CASI PHARMACEUTICALS Reports Q3 Revenue $7.8M - Marketscreener.com
CASI Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results - AccessWire
CASI Pharma Q3 Revenue Jumps 96% QoQ to $7.8M Despite Wider Losses, Advances Pipeline | CASI Stock News - StockTitan
CASI Pharmaceuticals Inc (CASI) Quarterly 10-Q Report - Quartzy
CASI Pharmaceuticals (NASDAQ:CASI) Share Price Passes Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat
CASI Pharmaceuticals (NASDAQ:CASI) Stock Crosses Above 200 Day Moving Average – Here’s Why - Defense World
CASI Pharmaceuticals (NASDAQ:CASI) Share Price Passes Above 200 Day Moving AverageTime to Sell? - MarketBeat
CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS - GuruFocus.com
(CASI) Proactive Strategies - Stock Traders Daily
CASI Pharmaceuticals gets China nod for ITP treatment trial - Investing.com
CASICASI Pharmaceuticals, Inc. Ordinary Shares Latest Stock News & Market Updates - StockTitan
CASI Pharmaceuticals Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia - AccessWire
CASI Pharmaceuticals, Inc. Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia - Marketscreener.com
CASI Pharmaceuticals (NASDAQ:CASI) Stock Price Crosses Above 200-Day Moving Average – Should You Sell? - Defense World
CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Short Interest Update - MarketBeat
Objective long/short (CASI) Report - Stock Traders Daily
Renaissance Technologies LLC Acquires 4,000 Shares of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) - Defense World
(CASI) Trading Report - Stock Traders Daily
CASI Pharmaceuticals (NASDAQ:CASI) Stock Price Crosses Above 200 Day Moving Average of $4.67 - MarketBeat
CASI Pharmaceuticals (NASDAQ:CASI) Stock Price Crosses Above 200-Day Moving Average of $4.67 - Defense World
CASI Pharmaceuticals (NASDAQ:CASI) shareholders are still up 129% over 1 year despite pulling back 22% in the past week - Yahoo Finance
CASI Pharmaceuticals (NASDAQ:CASI) pulls back 22% this week, but still delivers shareholders solid 129% return over 1 year - Simply Wall St
CASI Pharmaceuticals (NASDAQ:CASI) Stock Price Passes Above 200 Day Moving Average of $4.60 - MarketBeat
CASI Pharmaceuticals (NASDAQ:CASI) Shares Pass Above Two Hundred Day Moving Average of $4.60 - Defense World
Tumor Necrosis Factor Inhibitor Drugs Market Insights Discussed Regarding Trends and Forecast Report 2024-2033 - WhaTech
CASI Pharmaceuticals (NASDAQ:CASI) Shares Pass Above 200 Day Moving Average of $4.57 - Defense World
CASI Pharmaceuticals (NASDAQ:CASI) Stock Crosses Above 200-Day Moving Average of $4.57 - MarketBeat
(CASI) Investment Report - Stock Traders Daily
CASI Pharmaceuticals (NASDAQ:CASI) Share Price Crosses Above 200 Day Moving Average of $4.48 - MarketBeat
CASI Pharmaceuticals (NASDAQ:CASI) Share Price Crosses Above 200-Day Moving Average of $4.48 - Defense World
CASI Pharmaceuticals (NASDAQ:CASI) Stock Passes Above 200-Day Moving Average of $4.46 - Defense World
CASI Pharmaceuticals (NASDAQ:CASI) Stock Price Crosses Above Two Hundred Day Moving Average of $4.46 - MarketBeat
Short Interest in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Declines By 6.9% - Defense World
(CASI) Technical Pivots with Risk Controls - Stock Traders Daily
CASI Pharmaceuticals (NASDAQ:CASI) Announces Quarterly Earnings Results - Defense World
Idg Accel China Growth Fund Iii L.p. Net Worth (2024) - GuruFocus.com
CASI Stock Earnings: CASI Pharmaceuticals Beats EPS, Misses Revenue for Q2 2024 - MSN
CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2024 BUSINESS AND FINANCIAL RESULTS - PR Newswire
CASI Pharmaceuticals (NASDAQ:CASI) Share Price Passes Above 200 Day Moving Average of $4.47 - MarketBeat
Finanzdaten der Casi Pharmaceuticals Inc-Aktie (CASI)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.24%
0.94%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):